FDA Approves Novartis’ New IL-17A-Blocking Psoriasis Drug Cosentyx
Novartis' Cosentyx is the first approved human monoclonal antibody that selectively binds to interleukin IL-17A.
Novartis' Cosentyx is the first approved human monoclonal antibody that selectively binds to interleukin IL-17A.
Engineered for implants up to 1500cc, the next-generation delivery system supports a “no-touch” technique to improve control, reduce friction, and minimize risks such as infection and capsular contracture.